Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ: CGON )

26.01 -0.61 (-2.29%)
Streaming Delayed Price Updated: 3:54 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 315,946
Open 26.44
Bid (Size) 26.00 (1)
Ask (Size) 26.06 (1)
Prev. Close 26.62
Today's Range 25.39 - 26.58
52wk Range 23.91 - 46.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented 
From CG Oncology Inc.
Via GlobeNewswire
3 Analysts Assess CG Oncology: What You Need To Know
Via Benzinga

Performance

YTD
-10.22%
-10.22%
1 Month
-7.99%
-7.99%
3 Month
-18.03%
-18.03%
6 Month
-28.74%
-28.74%
1 Year
-27.08%
-27.08%

More News

Read More
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
Via Benzinga
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
Why CG Oncology (CGON) Stock Is Down 9%
Via Benzinga
Demystifying CG Oncology: Insights From 7 Analyst Reviews
Via Benzinga
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Pricing of Public Offering
From CG Oncology Inc.
Via GlobeNewswire
Nasdaq Jumps 300 Points To Record Highs
Via Talk Markets
Topics Stocks / Equities
A Closer Look at 9 Analyst Recommendations For CG Oncology
Via Benzinga
CG Oncology Announces Proposed Public Offering
From CG Oncology Inc.
Via GlobeNewswire
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate
Via Benzinga
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
Via InvestorPlace
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
From CG Oncology Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.